Cargando…
Tocilizumab monotherapy uncovered the role of the CCL22/17‐CCR4(+) Treg axis during remission of crescentic glomerulonephritis
OBJECTIVES: Tocilizumab (TCZ) is a humanised anti‐interleukin (IL)‐6 receptor (IL‐6R) monoclonal antibody that is a promising agent to treat various autoimmune diseases. However, the mechanism of TCZ efficacy is unclear. This study aims to elucidate the relationship between Tregs and IL‐6R blockade...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596393/ https://www.ncbi.nlm.nih.gov/pubmed/33163184 http://dx.doi.org/10.1002/cti2.1203 |